A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Completed · Phase 1/Phase 2

Conditions studied: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA

In brief

Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors. Part 2A (Completed Enrollment) and Part 2B (Completed Enrollment) - The purpose of the second part of the study is to determine the safety and clinical activity of the RP2D of oral rucaparib administered daily to patients with a known deleterious BRCA mutation (germline or somatic). Part 3 (Completed Enrollment) - The purpose of the third part of the study is to further evaluate PK of higher dose strength tablets at the RP2D in patients with any advanced solid tumor, inclusive of lymphoma, with evidence of a BRCA mutation (germline or somatic).

Key facts

Study ID

NCT01482715

Run by

pharmaand GmbH

People needed

136

Starts

2011-11-01

Expected to finish

2019-05-01

Last updated by the study team

2023-06-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Have a known deleterious BRCA mutation (gBRCA or sBRCA) (as determined by a local laboratory that has received an international or country-specific, quality standards certification)
• Have evidence of measurable disease as defined by RECIST Version 1.1
• Have sufficient archival FFPE tumor tissue available for planned analyses. Archival tissue from the most recently collected biopsy or debulking surgery should be provided, if available.
• Have a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Have received at least three prior chemotherapy regimens and have relapsed disease confirmed by radiologic assessment

You may not qualify if…

• Active second malignancy, i.e., patient known to have potentially fatal cancer present for which she may be (but not necessarily) currently receiving treatment
• a. Patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy was completed >6 months prior and/or bone marrow transplant (BMT) >2 years prior to first dose of rucaparib
• Prior treatment with any PARP inhibitor.
• Untreated or symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases are eligible provided they have been clinically stable for at least 4 weeks.
• Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs 14 days prior to first dose of rucaparib and/or ongoing adverse effects from such treatment > NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most recent treatment may be permitted with prior advanced approval from Sponsor).
• Hospitalization for bowel obstruction within 3 months prior to enrollment.

Where it is running

• UCSF — San Francisco, California, United States
• Sarah Cannon Research Institute — Sarasota, Florida, United States
• Dana-Farber Cancer Institute (Part 3 only) — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• Sheba Medical Center — Ramat Gan, Israel
• Tel Aviv Sourasky Medical Center — Tel Aviv, Israel
• Hospital Vall d'Hebron — Barcelona, Spain
• Guy's and St Thomas NHS Foundation Trust — London, England, United Kingdom
• Royal Marsden NHS Foundation Trust — London, England, United Kingdom
• Imperial College Healthcare — London, England, United Kingdom
• Newcastle University — Newcastle upon Tyne, England, United Kingdom
• Institution of Cancer Science, University of Glasgow Wolfson Wohl Cancer Research — Glasgow, Scotland, United Kingdom
• University College London Cancer Institute — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.